CD8A and COVID-19: We found an increase in TFH cells and alterations in TFH-TH1, TFH-TH2 and TFH-TH17 subsets that persisted following recovery from COVID-19, and a consistent rise in the CD8+ terminal effector memory RA+ (TEMRA) subset throughout the 6-7 months of the study.